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Summary 
Objective 
Many different gene families are currently being investigated for their potential role in 
epilepsy and in the response to antiepileptics. A common research challenge is identifying the 
members of a gene family that are most significantly dysregulated within the human epileptic 
focus, before taking them forward for resource-intensive functional studies. Published data 
about transcriptomic changes within the human epileptic focus remains incomplete. A need 
exists for an accurate in silico system for the prediction of dysregulated genes within the 
epileptic focus. We present such a bioinformatic system. We demonstrate the validity of our 
approach by applying it to the solute carrier (SLC) gene family. There are >400 known SLCs. 
SLCs have never been systematically studied in epilepsy.  
Methods 
Using our in silico system, we predicted the SLCs likely to be dysregulated in the epileptic 
focus. We validated our in silico predictions by identifying ex vivo the SLCs dysregulated in 
epileptic foci, and determining the overlap between our in silico and ex vivo results. For the 
ex vivo analysis, we used a custom oligonucletoide microarray containing exon probes for all 
known SLCs to analyse 24 hippocampal samples obtained from surgery for 
pharmacoresistant mesial temporal lobe epilepsy and 24 hippocampal samples from normal 
post-mortem controls.  
Results 
There was a highly significant (p <9.99x10-7) overlap between the genes identified by our in 
silico and ex vivo strategies. The SLCs identified were either metal ion exchangers or 
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neurotransmitter transporters, which are likely to play a part in epilepsy by influencing 
neuronal excitability.  
Significance 
The identified SLCs are most likely to mediate pharmacoresistance in epilepsy by enhancing 
the intrinsic severity of epilepsy, but further functional work will be needed to fully evaluate 
their role. Our successful in silico strategy can be adapted in order to prioritize genes relevant 
to epilepsy from other gene families.  
Key Points: 
1. We have developed a novel in silico strategy for predicting dysregulated genes in the 
human epileptic focus. 
2. A novel and appealing feature of our proposed system is the ability to validate the 
predicted genes in silico.   
3. Using this approach, followed by ex vivo validation, we have identified the SLC genes 
dysregulated in the epileptic human hippocampus. 
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Background 
Epilepsy is amongst the most common neurological disorders, with a prevalence of up to 1% 
of the population.1 Epilepsy is a complex genetic disease: genes from a number of different 
functional categories are likely to be involved in its pathogenesis, and many different gene 
families are currently being actively investigated for their potential role in epilepsy and in the 
response to antiepileptics2 A common research challenge is identifying the most dysregulated 
genes belonging to a particular functional group or gene family, before taking them forward 
for more arduous and resource-intensive functional studies. However, the low power of 
microarray studies on brain tissue from epilepsy surgery, because of their small sample sizes, 
means that published data about transcriptomic changes within the human epileptic focus is 
still incomplete.3 Identifying dysregulated genes in human epileptic brain tissue is far from a 
trivial undertaking: obtaining sufficient amounts of precious brain tissue and the cost of 
quantifying the expression of potentially hundreds of constituents of a gene family is a major 
challenge. It will be of use, therefore, to have an easily applicable strategy that uses 
publically available data and computational tools to identify and then validate in silico genes 
dysregulated in the epileptic focus. The identified genes could then be further verified ex 
vivo. In the present work, we present such a strategy, and demonstrate its validity by applying 
it to the solute carrier (SLC) superfamily. 
Most patients with epilepsy become seizure-free with antiepileptic drug (AED) therapy. 
However, approximately 30% of epilepsy patients are pharmacoresistant: they continue to 
experience seizures even if treated with various AEDs at maximal dosages.4 A number of 
hypotheses have been put forward to explain pharmacoresistance;5 one of these is the 
multidrug transporter (MDT) hypothesis. According to this hypothesis, pharmacoresistance is 
a consequence of decreased drug concentrations at the epileptic focus secondary to a 
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localized dysregulation of drug transporters,5 which could either increase drug efflux from or 
reduce influx into the epileptic focus. The largest superfamily of MDTs is the SLC 
superfamily which are mainly influx transporters.6 Down regulation of SLC transporters that 
are normally expressed at significant levels in the epileptic focus could thus potentially 
contribute to the development of pharmacoresistance. There are approximately 400 known 
SLC proteins in total, but very few of these have been studied in epilepsy. Mesial temporal 
lobe epilepsy (MTLE), in which seizures originate from the hippocampus, is the most 
common cause of refractory epilepsy and the most common indication for epilepsy surgery.7 
We focused, therefore, on SLCs most relevant to this phenotype. We devised a 
comprehensive in silico approach that exploited relevant published data and built upon them 
using computational tools in order to identify the SLCs which are downregulated in the 
pharmacoresistant epileptic focus. We then validated the output from the in silico approach 
using an analysis of human brain tissue ex vivo.  
We anticipate that our in silico strategy will also be adaptable to other pathologies and gene 
families.  
Methods: 
In silico analysis 
Our in silico strategy was as follows:  
1. Rank SLCs based on the strength of the published evidence of their downregulation in 
pharmacoresistant epileptic foci, if such data were available. 
2. For SLCs with no such published data, rank genes based on the computationally-
determined likelihood of their down regulation in pharmacoresistant epileptic foci. 
The individual steps and processes are illustrated schematically in Fig. 1. 
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Integrative analysis of microarray studies: We started by integrating the results of large-
scale gene expression profiling studies on brain tissue from epilepsy surgery—details of this 
analysis can be found in our previously published study.3 Data relating to SLCs from this 
analysis were carried forward into a convergent functional genomics approach.  
Convergent functional genomics (CFG): CFG is an approach for prioritizing candidate 
genes for complex disorders by integrating and tabulating multiple lines of evidence, such as 
human and animal-model gene and protein expression data.8 In order to implement the CFG 
approach, each SLC transporter was scored on the strength of the evidence of down-
regulation of the gene or protein in epileptic foci of humans or of animal models of 
pharmacoresistant epilepsy. The search strategy and search terms used in order to find this 
data is detailed in the Supplementary Material. Details of the scoring system are given in 
Table 1.  
Computational gene prioritization (CGP): To perform CGP, we used a freely-available 
bioinformatics software application called Endeavour9 whose key feature is that it uses 
multiple genomic data sources (e.g. sequence, expression, literature and annotation) to 
estimate how promising a candidate gene is by measuring its similarity with a set of training 
genes. A detailed explanation of the principles and protocols underlying Endeavour can be 
found in its original publication.9 Our training gene set comprised the top scoring SLCs from 
the CFG step, with strong replicated published evidence in support of a role in epilepsy 
pharmacoresistance. The validity of the CGP result is critically dependent on the quality of 
the training set. Therefore, to ensure the quality of the training set, we performed a 
comprehensive literature review of our training genes to show that they are highly likely to be 
involved in epilepsy pharmacoresistance, and performed leave-one-out analysis (LOOA); 
please see details in the Supplementary Material.  
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Our candidate gene set comprised SLCs that are most abundantly expressed in normal human 
hippocampus. In order to identify the most abundant SLCs, we performed a ‘meta-analysis’ 
of publically available genome-wide gene expression studies. The methods of this meta-
analysis are detailed in the supplementary material and summarized here. Briefly: (1) We 
downloaded genome-wide gene expression data for 73 normal hippocampal tissue samples 
from four different published Affymetrix GeneChip Human Genome U133 Plus 2.0 Array 
studies; (2) We filtered out non-expressed genes based on ‘fraction present’ according to 
Affymetrix Microarray Suite 5.0 (MAS5) detection call—we only retained genes present in 
more than 50% of the samples. (3) The retained genes were then ranked by transcript 
abundance—we used rank product (a non-parametric statistic that detects items that are 
consistently highly ranked in a number of lists) to create one combined hierarchical list of 
transcript abundance. (4) From this analysis, the 50 most abundant SLCs were chosen as the 
candidate gene set—all these genes had a false discovery rate (FDR) of less than 5% for 
being ranked amongst the 50 most abundant SLC genes. 
Computational verification of CGP results: To validate our CGP approach and prioritized 
lists, the following steps were undertaken: 
We set up an in silico experiment. For this experiment, we created (i) a ‘positive control’ 
training set comprising the most consistently down-regulated genes from our previously 
mentioned integrative analysis of gene-expression profiling studies on brain tissue from 
epilepsy surgery3 and (ii) a ‘negative control’ training set consisting of randomly chosen 
genes from our integrative analysis. Both the control training sets were used to perform CGP 
of the 50 candidate SLC genes.  The list of genes comprising the control training sets can be 
found in the Supplement. We hypothesized that the ‘positive control ranking’ would be 
significantly similar to the original ranking, whereas the ‘negative control ranking’ would be 
dissimilar to the original ranking. We compared the original CGP ranking to the positive 
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control and negative control CGP rankings in turn, using objective validated statistical 
methods: hypergeometric equation to determine the statistical significance of the size of the 
overlap between lists, and Bioconductor package OrderedList10 to calculate the statistical 
significance of rank order similarity (see details in the Supplementary Material). 
Creation of the final in silico gene list: To create the final in silico list of 20 genes, we 
amalgamated the CFG and CGP results. Giving precedence to genes with direct published 
evidence of down regulation, CFG genes were placed at the top of the list in rank order, 
followed by the CGP genes, with a cut-off being applied at a total of 20 genes. As our chosen 
cut-off of 20 total genes could be deemed arbitrary, we created two further lists of 10 and 30 
total genes for testing. 
Ex vivo analysis 
For ex vivo validation, we performed exon array analysis of 24 hippocampal samples from 
surgery for pharmacoresistant mesial temporal lobe epilepsy and obtained 24 histologically-
normal post-mortem hippocampal samples from donors with no known brain disease. The 
whole-transcript amplification protocol of exon arrays allows more accurate measurement of 
gene expression than standard microarrays.11-13 Details of the ex vivo methods are provided in 
the Supplementary Material. 
Overlap between computational and microarray results 
The statistical significance of the overlap between the computationally-generated gene list 
and the list of SLCs found to be significantly downregulated in our microarray was calculated 
using the R function phyper. 
 
Results 
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In silico analysis 
Integrative analysis of microarray studies: The full results of this analysis can be found in 
our previously published study.3 Data relating to SLCs from this analysis were carried 
forward into a convergent functional genomics step.  
Convergent functional genomics (CFG): The results of the CFG analysis showed that the 
final score was 1.5 for SLC1A2, SLC1A3, SLC17A7; 1.0 for SLC24A3, SLC2A3, SLC12A5; 
and 0.5 for SLC30A3, SLC8A2, SLC47A1, SLC4A8, SLC15A2, SLC8A1, SLC17A1, SLC6A20, 
SLC16A1, SLC1A6, SLC1A1. References for these data used can be found in the 
Supplementary Material.  
There was data in the published literature relating only to these 17 SLC transporters. We also 
wished to obtain a prioritized list of SLC transporters that have hence far been overlooked in 
epilepsy research. To do this, we used the software ‘Endeavour’ to perform computational 
gene prioritization.  
Computational Gene Prioritization (CGP): To create a training gene set, we utilized the 
six SLC transporters (SLC1A2, SLC1A3, SLC2A3, SLC12A5, SLC17A7 and SLC24A3) with 
the highest CFG scores and with replicated evidence in support of a role in epilepsy 
pharmacoresistance. To assess the quality of our chosen training set, we performed leave-
one-out cross-validation. The results of this analysis showed that four defector genes were 
ranked first, while two were ranked second (see Supplementary Material). This demonstrates 
that the training set is homogenous. We also performed a comprehensive literature review of 
our training genes to show that they are highly likely to be involved in epilepsy (see 
Supplementary Material). For example, studies in animal models reveal that a reduction in 
SLC12A5 expression results in an increased susceptibility to the development of seizures: 
complete deletion of SLC12A5 is incompatible with life,14 a 95% reduction in SLC12A5 
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expression results in handling-induced seizure behaviour,15 and heterozygous animals have a 
lower threshold for epileptic seizures—electrophysiological measurements in the 
hippocampus show hyperexcitability and animals demonstrate a twofold increase in 
pentylenetetrazole-induced seizures.15 SLC2A3 heterozygous null mice have a lower seizure 
threshold and all develop clinical or subclinical electroencephalographically-evident 
spontaneous seizures after hypoxic-ischaemia while wildtype mice do not.16; 17 Monozygous 
mice deficient in SLC1A2 show lethal spontaneous seizures.18   
The candidate gene set for CGP comprised the 50 most abundant SLC transporters in the 
normal human hippocampus, identified by performing a microarray meta-analysis as 
described in the Methods section.  
The results of the CGP are tabulated in the Supplementary Material. As in silico verification, 
this CGP ranking was compared with a ‘positive control’ CGP ranking, generated using a 
‘positive control’ training set comprising the 10 genes most consistently downregulated in an 
integrative analysis of microarray studies on brain tissue from epilepsy surgery:3 there was a 
statistically significant overlap in the top 20 genes of the two lists (p=0.004) and significant 
similarity between the order of genes in the two lists (p=0.01). In contrast, when the original 
CGP ranking was compared with a ‘negative control’ CGP ranking, generated using a 
‘negative control’ training set of 10 randomly chosen genes from our integrative analysis, 
there was no significant overlap in the top 20 genes of the two lists (p=0.614) and no 
significant similarity between the order of genes in the two lists (p=0.10).  
Creation of the final in silico gene list: To create the final in silico list of 20 genes, we 
amalgamated the CFG and CGP results. Giving precedence to genes with direct published 
evidence of down regulation, CFG genes were placed at the top of the list in rank order, 
followed by the CGP genes, with a cut-off being applied at a total of 20 genes. As our chosen 
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cut-off of 20 total genes could be deemed arbitrary, we created two further lists of 10 and 30 
total genes for testing. 
 
Ex vivo analysis 
For ex vixo validation, we collected 24 hippocampal samples from surgery for 
pharmacoresistant mesial temporal lobe epilepsy and obtained 24 histologically-normal post-
mortem hippocampal samples from donors with no known brain disease. Important patient 
and donor individual and sample characteristics are summarized in Table 3. Eighteen SLC 
genes (Table 4) were found to be significantly downregulated (FDR < 0.05, fold change ≥ 
1.5).  Detailed results of the ex vivo analysis are provided in the supplementary material. 
MIAME-compliant data has been deposited in ArrayExpress (E-MTAB-3123). 
 
Overlap between computational and microarray results: We calculated the size of the 
overlap between the 18 SLC genes shown to be down-regulated by our microarray and our in 
silico gene lists of 10, 20 and 30 SLC genes respectively. All three overlaps were highly 
significant, with p-values of 8.41 x 10-7, 7.86 x 10-6 and 9.99 x 10-7 respectively. 
When creating the candidate gene list for CGP, we adopted a robust filtering approach, which 
has been described in detail above. We determined if our robust approach to candidate gene 
set selection improved the results of the CGP. If no filters were applied to the candidate gene 
set, the overlap between the top CGP and microarray results was not statistically significant 
(p=0.386). But by filtering into the candidate set genes which were present in more than 50% 
of meta-analysis samples and were amongst the 50 most abundant SLCs, the overlap of the 
top CGP and microarray results became statistically significant (p=0.009). 
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Discussion: 
In silico strategy 
We have developed a novel in silico pipeline for the prediction of dysregulated genes in the 
human epileptic focus. This methodical stepwise pipeline systematically integrates 
complementary strategies: integrative analysis of large-scale transcriptomic studies, CFG and 
CGP. Although this approach might be deemed intuitive, it has never been formalized, 
validated and presented before. This pipeline was highly effective in predicting significantly 
downregulated SLCs in the pharmacoresistant epileptic human hippocampus. We highlight 
the following noteworthy elements of our in silico strategy that are particularly responsible 
for its success: 
This strategy is based on a foundation of good research practice, as the first steps are to 
collate and systematically integrate all relevant data already published, including the results 
of whole-genome microarray studies. When compiling the final in silico gene list, we give 
precedence to genes with direct published evidence of dysregulation; most biologists will 
agree with this strategy. Systematically collecting data and then scoring it using a pre-defined 
scoring system (CFG) is also important for creating an unbiased training set for CGP. The 
methodical stepwise nature of the pipeline will appeal to researchers. Another appealing 
aspect is that the output from each step is validated before carrying it forward into the next 
step. In particular, the prioritized gene list from the CGP step is validated using a novel 
approach, by performing an in silico experiment with positive and negative control training 
sets. The latter validation step is an especially valuable feature as it may alert researchers to 
erroneous CGP results before resource-intensive wet-lab experiments are undertaken. 
An important feature of the pipeline is being selective in creating the candidate gene-set for 
CGP. This point has not been sufficiently highlighted in previous work on CGP. Our robust 
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approach to candidate gene set selection improved the results of the CGP—by filtering out 
SLCs from the candidate set that were less likely to be relevant, more relevant SLCs were 
ranked more favourably. 
We acknowledge that the performance of this system with different phenotypes and gene 
groups will vary depending on the quality and quantity of published data available. However, 
when published data is sparse, adopting the robust systematic approaches advocated here 
becomes even more important. 
Ex vivo validation 
To ensure that our ex vivo validation was robust, we chose to make use of an exon array.  
Table 5 summarizes the functions of the 18 SLC transporters found to be downregulated in 
our exon array. As can be seen from Table 5, the vast majority of the identified SLC proteins 
are either small metal ion exchangers or transporters of neurotransmitters, particularly 
glutamate. Given the key roles played by ionic transport and glutamatergic transmission in 
neuronal function, it stands to reason that these should be the most important SLC proteins in 
the epileptic hippocampus. The potential role of these transporters in epilepsy is also 
supported by evidence from published literature. For example, SLC12A5 is a neuron-specific 
potassium-chloride symporter expressed throughout the central nervous system.19-21 Studies 
in animal models reveal that a reduction in SLC12A5 expression results in an increased 
susceptibility to the development of seizures: complete deletion of SLC12A5 is incompatible 
with life,14 a 95% reduction in SLC12A5 expression results in handling-induced seizure 
behaviour,15 and heterozygous animals have a lower threshold for epileptic seizures—
electrophysiological measurements in the hippocampus show hyperexcitability and animals 
demonstrate a twofold increase in pentylenetetrazole-induced seizures.15 An example of a 
neurotransmitter transporter is the glutamate transporter SLC25A22; mutations in this gene 
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cause various epilepsy syndromes.22-27 Further examples of the potential role in epilepsy of 
the identified SLCs are provided in the Supplementary Material. 
It should be noted that for SLC transporters of metal ions, there is as yet no evidence of non-
endogenous substrate transport—their small endogenous ionic substrates are markedly 
dissimilar to most xenobiotics, so it might be expected that they are not readily involved in 
xenobiotic transport.28 Similarly, there is no evidence as yet that the transporters of glutamate 
or of other neurotransmitters are able to transport therapeutic drugs. Therefore, while these 
SLCs potentially mediate pharmacoresistance in epilepsy, it is unlikely that they do this 
through altered transport of AEDs, but rather by enhancing the intrinsic severity of 
epilepsy.29 It is of course possible that some of the genetic changes identified in this analysis 
are the consequence, rather than the cause, of refractory seizures. The causative role of the 
genes identified as potentially playing a part in the development of pharmacoresistance will 
need to be established with future functional studies.  
Conclusions 
We have developed a novel in silico strategy that can aid epilepsy research by prioritizing 
specific genes for study from within large gene sets. We have identified the most 
significantly downregulated SLCs in the pharmacoresistant epileptic human hippocampus. 
The role of these SLCs in the epileptic hippocampus will need to be defined through future 
functional studies. 
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Legend to Figure 
Figure 1 Our in silico strategy. We extracted data relating to SLCs from (1) an integrative 
analysis of microarray studies on brain tissue from epilepsy surgery, and (2) a comprehensive 
review of published literature on epilepsy pharmacoresistance, and integrated all the data 
using ‘convergent functional genomics (CFG)’—a validated technique for prioritizing genes 
involved in complex diseases by collating evidence using a pre-defined scoring system. To 
identify SLCs which have not been studied in epilepsy pharmacoresistance but could 
potentially be involved, we employed a computational gene prioritization tool called 
Endeavour, using SLCs with the highest CFG-scores as the training genes. We validated this 
computationally prioritized gene list by (1) prioritizing the same candidate genes using a 
robust independent ‘positive control’ training set comprising the 10 most consistently 
downregulated genes from the aforementioned integrative analysis and, then, demonstrating 
significant similarity with the original list, and (2) prioritizing the same candidate genes using 
a ‘negative control’ training set comprising 10 randomly chosen genes from the 
aforementioned integrative analysis and demonstrating no significant rank order similarity 
with the original list. 
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Table 1 Convergent Functional Genomics scoring scheme for SLC transporters 
Evidence Score Reason 
Gene/protein expression data   
Downregulated in ≥2 studies on 
pharmacoresistant MTLE epileptic foci 
1 Maximum weight given to confirmed 
downregulation in MTLE, which is our 
phenotype of interest 
Downregulated in only 1 study on 
pharmacoresistant MTLE epileptic foci 
0.50 Lower score given to non-replicated evidence 
Downregulated in ≥1 study on 
pharmacoresistant non-MTLE epileptic 
foci 
0.50 Lower score given to evidence in other 
phenotypes 
Evidence of downregulation in brain 
tissue from animal models of 
pharmacoresistant epilepsy 
0.25 Lowest score for animal models 
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Table 2 In silico gene list of 30 genes. 
In silico list of 30 genes 
SLC1A2 
SLC1A3 
SLC17A7 
SLC24A3 
SLC2A3 
SLC12A5 
SLC30A3 
SLC8A2 
SLC47A1 
SLC4A8 
SLC15A2 
SLC8A1 
SLC17A1 
SLC6A20 
SLC16A1 
SLC1A6 
SLC1A1 
SLC1A4 
SLC6A1 
SLC24A2 
SLC12A7 
SLC25A22 
SLC6A8 
SLCO1C1 
SLC7A5 
SLCO3A1 
SLC7A11 
SLC25A11 
SLC4A3 
SLC20A1 
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Table 3 Sample characteristics. RIN=RNA Integrity Number 
Sample Phenotype Age Sex RIN 
D1 Case 41 F 7.4 
D2 Case 23 F 6.8 
D3 Case 51 M 6 
D4 Case 49 F 6.9 
D5 Case 50 F 7.8 
D6 Case 45 F 6.6 
D7 Case 12 M 7 
D8 Case 29 F 7.8 
D9 Case 33 M 6.8 
D10 Case 25 F 7.1 
D11 Case 34 M 7 
D12 Case 33 M 8.8 
D13 Case 33 M 8.6 
D14 Case 22 F 7.3 
D15 Case 48 M 7.6 
D16 Case 39 F 7.4 
D17 Case 29 F 7.1 
D18 Case 44 M 7.9 
D19 Case 40 F 6.6 
D20 Case 48 M 8.5 
D21 Case 23 M 8.4 
D22 Case 63 M 7.9 
D23 Case 31 M 8.2 
D24 Case 27 F 8.2 
N1 Control 81 M 6.5 
N2 Control 78 F 6.2 
N3 Control 84 F 6.6 
N4 Control 91 F 6.7 
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N5 Control 88 M 6.3 
N6 Control 38 M 6.1 
N7 Control 50 M 6.2 
N8 Control 45 M 6.3 
N9 Control 39 M 6.1 
N10 Control 40 M 6 
N11 Control 61 M 6.2 
N12 Control 63 F 6.2 
N13 Control 66 M 6.2 
N14 Control 22 F 6.3 
N15 Control 27 M 6.3 
N16 Control 45 M 6.9 
N17 Control 44 F 6.7 
N18 Control 50 M 6.5 
N19 Control 43 M 6.6 
N20 Control 46 M 6.8 
N21 Control 51 M 6.2 
N22 Control 48 M 6 
N23 Control 43 M 6.6 
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Table 4 Microarray results. FDR=false discovery rate 
Gene Symbol Microarray results 
FDR Fold-change 
SLC24A3 1.65 x10-4 3.7 
SLC47A1 1.49 x10-3 2.6 
SLC25A23 3.38 x10-4 2.3 
SLC8A2 1.64 x10-5 2.0 
SLC17A7 3.89 x10-3 1.8 
SLC25A41 1.20 x10-5 1.6 
SLC26A10 5.28 x10-5 1.6 
SLC4A3 8.02 x10-5 1.6 
SLC4A7 2.26 x10-2 1.6 
SLC12A5 1.24 x10-2 1.6 
SLC7A1 6.81 x10-5 1.6 
SLC16A2 3.38 x10-4 1.6 
SLC25A22 1.88 x10-4 1.6 
SLC29A4 1.22 x10-3 1.5 
SLC8A1 1.24 x10-2 1.5 
SLC35E2 6.80 x10-4 1.5 
SLC4A8 1.83 x10-4 1.5 
SLC18A2 2.89 x10-2 1.5 
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Table 5 Functions of the 18 SLC proteins found to be downregulated in the exon microarray. 
Data from Gene (http://www.ncbi.nlm.nih.gov/gene) and UniPort 
(http://www.uniprot.org/help/uniprotkb). 
Gene Symbol Function 
SLC24A3 Calcium, potassium:sodium antiporter activity 
SLC47A1 Monovalent cation:hydrogen antiporter activity 
SLC25A23 Calcium-dependent mitochondrial solute carrier activity 
SLC8A2 Sodium:calcium exchange activity 
SLC17A7 L-glutamate transmembrane transporter activity 
SLC25A41 Mitochondrial ATP-magnesium:phosphate carrier activity 
SLC26A10 Anion exchange activity 
SLC4A3 Anion exchange activity 
SLC4A7 Sodium bicarbonate cotransporter activity 
SLC12A5 Potassium:chloride transporter activity 
SLC7A1 Transport of the cationic amino acids (arginine, lysine and ornithine) 
SLC16A2 Thyroid hormone transporter 
SLC25A22 Transport of glutamate across the inner mitochondrial membrane 
SLC29A4 Reuptake of monoamines into presynaptic neurons 
SLC8A1 Sodium:calcium exchanger activity 
SLC35E2 Transport of nucleotide sugars into endoplasmic reticulum and Golgi bodies 
SLC4A8 Sodium- and carbonate-dependent chloride:bicarbonate exchange activity 
SLC18A2 Vesicular transport of biogenic amine neurotransmitters 
 
 
